The Antiarrhythmic Medicine market in Norway has seen a continuous decline. In 2023, the sales stood at $2.8 million PPP. From 2024 to 2028, forecast data shows a decrease from $2.6 million PPP to $1.9 million PPP, demonstrating a consistent downward trend. On a year-on-year basis, the variations are: -11.5% (2024-2025), -8.7% (2025-2026), -4.8% (2026-2027), and -5% (2027-2028). The Compound Annual Growth Rate (CAGR) indicates an average annual decrease of approximately 7% over the five-year period from 2023 to 2028.

Future trends to watch for:

- Emerging technologies and treatments in the cardiology sector could influence the demand for traditional antiarrhythmic medicines.
- Changing healthcare policies and reimbursement rates in Norway might impact sales volumes.
- Increasing focus on preventive measures and healthy lifestyle awareness could reduce the need for such medications.
- Competitive market dynamics with potential new entrants or new formulations impacting the market share of existing medications.